Ailux Presents New Preclinical Data Supporting its Long-Acting IL-4Rα Antibody and Expanding its Bispecific Applications at EADV 2026

SHANGHAI, LONDON & SOMERVILLE, October 7, 2026 — Ailux, an AI-native biotech company developing next-generation biologics, today announced preclinical findings presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The oral presentation highlighted the company’s long-acting IL-4Rα antibody, engineered for extended half-life via pH-sensitive IL-4Rα binding. The IL-4Rα antibody also retained functional […]